Funding for this research was provided by:
National Natural Science Foundation of China (31772271)
International Science and Technology Cooperation Programme (2019YFE0106600)
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201826)
OeAD-GmbH (CN 14/2020)
Received: 24 August 2020
Accepted: 29 October 2020
First Online: 18 November 2020
Ethics approval and consent to participate
: Written consent was obtained from all participants (or their representatives) and the study was approved by the local ethics committee (authorization No. 2011-R-1 and 2019-312, Second Affiliated Hospital, College of Medicine, Zhejiang University), in collaboration with the Third People’s Hospital of Datong, Shanxi (authorization No. 2015-001), the First Affiliated Hospital, Shanxi Medical University (2019 K-K0007), Beijing Shijitan Hospital, Capital Medical University (authorization No. 2015-003). Yu Huang Ding Hospital, Yantai, Shandong (authorization No. 2015-164), and Qvjing Chinese Traditional Medicine Hospital, Yunnan, China. The antibodies were produced by Hua An Biotech Ltd., Hangzhou, China (authorization No. SCXK 2016-0004 and SCXK 2017-0004).
: Gao ZS received a grant from Hangzhou Aileji Biotech Company, Hangzhou, China (Contract 2016R1). Gao ZS, Liu Y and Feng Y received funds from The Ministry of Science and Technology China (2019YFE0106600). Wang XY received a grant from Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201826). Rudolf Valenta has received research grants from Viravaxx, Vienna, Austria and HVD Life Sciences, Vienna, Austria and serves as a consultant for Viravaxx. Susanne Vrtala received funds from the Austrian government (CN 14/2020). A patent for Artemisia pollen allergen nsLTP quantification by ELISA has been applied in China (202011210352.1, pending) by ZS Gao, L Zhao, BY Gao and WY Fu. All other authors declare no conflict of interest.